- Home
- ESPR vs SABA Comparison
ESPR vs SABA Comparison
Compare ESPR & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- SABA
- Stock Information
- Founded
- ESPR 2008
- SABA 1988
- Country
- ESPR United States
- SABA United States
- Employees
- ESPR N/A
- SABA N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- ESPR Health Care
- SABA
- Exchange
- ESPR Nasdaq
- SABA Nasdaq
- Market Cap
- ESPR 220.0M
- SABA 254.3M
- IPO Year
- ESPR 2013
- SABA N/A
- Fundamental
- Price
- ESPR $2.17
- SABA $9.24
- Analyst Decision
- ESPR Buy
- SABA
- Analyst Count
- ESPR 6
- SABA 0
- Target Price
- ESPR $6.50
- SABA N/A
- AVG Volume (30 Days)
- ESPR 5.2M
- SABA 290.0K
- Earning Date
- ESPR 08-05-2025
- SABA 01-01-0001
- Dividend Yield
- ESPR N/A
- SABA 12.91%
- EPS Growth
- ESPR N/A
- SABA N/A
- EPS
- ESPR N/A
- SABA N/A
- Revenue
- ESPR $268,125,000.00
- SABA N/A
- Revenue This Year
- ESPR $6.10
- SABA N/A
- Revenue Next Year
- ESPR N/A
- SABA N/A
- P/E Ratio
- ESPR N/A
- SABA N/A
- Revenue Growth
- ESPR N/A
- SABA N/A
- 52 Week Low
- ESPR $0.69
- SABA $3.64
- 52 Week High
- ESPR $3.94
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- ESPR 73.45
- SABA 49.45
- Support Level
- ESPR $2.00
- SABA $9.12
- Resistance Level
- ESPR $2.14
- SABA $9.35
- Average True Range (ATR)
- ESPR 0.15
- SABA 0.10
- MACD
- ESPR 0.02
- SABA -0.03
- Stochastic Oscillator
- ESPR 95.08
- SABA 35.29
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.